CoChat
Sign Up
Cited by 287

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Curcumin and colorectal cancer: An update and current perspective on this natural medicine

Weng, Wenhao, Goel, Ajay·2022·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2020.02.011PMC PMC7438305
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2020.02.011

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 160

  1. Obrand, 1997, Incidence and patterns of recurrence following curative resection for colorectal carcinoma, Dis. Colon Rectum, 40, 15, 10.1007/BF02055676 · DOI
  2. O’Connell, 2008, Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set, J. Clin. Oncol., 26, 2336, 10.1200/JCO.2007.15.8261 · DOI
  3. Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J. Clin. Oncol., 27, 3109, 10.1200/JCO.2008.20.6771 · DOI
  4. Allen, 2019, Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development, Genome Med., 11, 11, 10.1186/s13073-019-0621-2 · DOI
  5. Farhana, 2018, Role of microbiome in carcinogenesis process and epigenetic regulation of colorectal cancer, Methods Mol. Biol., 1856, 35, 10.1007/978-1-4939-8751-1_3 · DOI
  6. Chen, 2018, The role of the gut microbiome in colorectal cancer, Clin. Colon Rectal Surg., 31, 192, 10.1055/s-0037-1602239 · DOI
  7. Bachmeier, 2018, The role of curcumin in prevention and management of metastatic disease, Int. J. Mol. Sci., 19, 10.3390/ijms19061716 · DOI
  8. Chikara, 2018, Oxidative stress and dietary phytochemicals: role in cancer chemoprevention and treatment, Cancer Lett., 413, 122, 10.1016/j.canlet.2017.11.002 · DOI
  9. Allegra, 2017, Anticancer activity of curcumin and its analogues: preclinical and clinical studies, Cancer Invest., 35, 1, 10.1080/07357907.2016.1247166 · DOI
  10. Goel, 2010, Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs, Nutr. Cancer, 62, 919, 10.1080/01635581.2010.509835 · DOI
  11. Goel, 2008, Multi-targeted therapy by curcumin: how spicy is it?, Mol. Nutr. Food Res., 52, 1010, 10.1002/mnfr.200700354 · DOI
  12. Goel, 2008, Curcumin as “Curecumin”: from kitchen to clinic, Biochem. Pharmacol., 75, 787, 10.1016/j.bcp.2007.08.016 · DOI
  13. Link, 2013, Curcumin modulates DNA methylation in colorectal cancer cells, PLoS One, 8, 10.1371/journal.pone.0057709 · DOI
  14. Ravindranathan, 2018, A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer, Sci. Rep., 8, 13869, 10.1038/s41598-018-32267-8 · DOI
  15. Shakibaei, 2014, Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures, PLoS One, 9, 10.1371/journal.pone.0085397 · DOI
  16. Shakibaei, 2015, Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer, BMC Cancer, 15, 250, 10.1186/s12885-015-1291-0 · DOI
  17. Shakibaei, 2013, Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways, PLoS One, 8, 10.1371/journal.pone.0057218 · DOI
  18. Toden, 2015, Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer, Cancer Prev. Res. (Phila), 8, 431, 10.1158/1940-6207.CAPR-14-0354 · DOI
  19. Toden, 2015, Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer, Carcinogenesis, 36, 355, 10.1093/carcin/bgv006 · DOI
  20. Willenbacher, 2019, Curcumin: new insights into an ancient ingredient against cancer, Int. J. Mol. Sci., 20, 10.3390/ijms20081808 · DOI
  21. Hu, 2017, Curcumin in hepatobiliary disease: pharmacotherapeutic properties and emerging potential clinical applications, Ann. Hepatol., 16, 835, 10.5604/01.3001.0010.5273 · DOI
  22. Goncalves, 2019, Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD), Eur. J. Med. Chem., 163, 911, 10.1016/j.ejmech.2018.12.020 · DOI
  23. Khan, 2019, Mechanistic insights of hepatoprotective effects of curcumin: therapeutic updates and future prospects, Food Chem. Toxicol., 124, 182, 10.1016/j.fct.2018.12.002 · DOI
  24. Chen, 2018, The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway, Int. J. Mol. Sci., 19, 10.3390/ijms19092729 · DOI
  25. Chandran, 2012, A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis, Phytother. Res., 26, 1719, 10.1002/ptr.4639 · DOI
  26. Sanmukhani, 2014, Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial, Phytother. Res., 28, 579, 10.1002/ptr.5025 · DOI
  27. Eke-Okoro, 2018, Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia, J. Clin. Pharm. Ther., 43, 460, 10.1111/jcpt.12703 · DOI
  28. Naeini, 2019, Antitumor effects of curcumin: a lipid perspective, J. Cell. Physiol., 10.1002/jcp.28262 · DOI
  29. Mirzaei, 2018, MicroRNA: a novel target of curcumin in cancer therapy, J. Cell. Physiol., 233, 3004, 10.1002/jcp.26055 · DOI · Paper page
  30. Carlos-Reyes, 2019, Dietary compounds as epigenetic modulating agents in cancer, Front. Genet., 10, 79, 10.3389/fgene.2019.00079 · DOI
  31. Bahrami, 2017, Therapeutic potential of targeting Wnt/beta-catenin pathway in treatment of colorectal cancer: rational and progress, J. Cell. Biochem., 118, 1979, 10.1002/jcb.25903 · DOI
  32. Salehi, 2019, The therapeutic potential of curcumin: a review of clinical trials, Eur. J. Med. Chem., 163, 527, 10.1016/j.ejmech.2018.12.016 · DOI
  33. Cani, 2018, Human gut microbiome: hopes, threats and promises, Gut, 67, 1716, 10.1136/gutjnl-2018-316723 · DOI · Paper page
  34. Rajagopala, 2017, The human microbiome and Cancer, Cancer Prev. Res. (Phila), 10, 226, 10.1158/1940-6207.CAPR-16-0249 · DOI
  35. Chen, 2019, Effects of intestinal microbial(-)elaborated butyrate on oncogenic signaling pathways, Nutrients, 11, 10.3390/nu11051026 · DOI
  36. Chung, 2018, Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells, Cell Host Microbe, 23, 203, 10.1016/j.chom.2018.01.007 · DOI
  37. Zhang, 2018, Association between Fusobacterium nucleatum and colorectal cancer: progress and future directions, J. Cancer, 9, 1652, 10.7150/jca.24048 · DOI
  38. Yang, 2017, Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear Factor-kappaB, and up-regulating expression of MicroRNA-21, Gastroenterology, 152, 851, 10.1053/j.gastro.2016.11.018 · DOI
  39. Brennan, 2019, Fusobacterium nucleatum – symbiont, opportunist and oncobacterium, Nat. Rev. Microbiol., 17, 156, 10.1038/s41579-018-0129-6 · DOI · Paper page
  40. Gholizadeh, 2017, Carcinogenesis mechanisms of Fusobacterium nucleatum, Biomed. Pharmacother., 89, 918, 10.1016/j.biopha.2017.02.102 · DOI
  41. Zhou, 2018, Fusobacterium and colorectal cancer, Front. Oncol., 8, 371, 10.3389/fonc.2018.00371 · DOI
  42. Ohno, 2017, Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells, PLoS One, 12, 10.1371/journal.pone.0185999 · DOI
  43. Peterson, 2018, Effects of turmeric and curcumin dietary supplementation on human gut microbiota: a double-blind, randomized, placebo-controlled pilot study, J. Evid. Based Integr. Med., 23, 10.1177/2515690X18790725 · DOI
  44. Mori, 2019, Gut microbiota analysis in postoperative lynch syndrome patients, Front. Microbiol., 10, 1746, 10.3389/fmicb.2019.01746 · DOI
  45. Youssef, 2018, Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms, Dig. Dis. Sci., 63, 2950, 10.1007/s10620-018-5190-5 · DOI
  46. Li, 2019, Intervention with alpha-ketoglutarate ameliorates colitis-related colorectal carcinoma via modulation of the gut microbiome, Biomed Res. Int., 2019
  47. McFadden, 2015, The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention, Inflamm. Bowel Dis., 21, 2483, 10.1097/MIB.0000000000000522 · DOI
  48. Burge, 2019, Curcumin and intestinal inflammatory diseases: molecular mechanisms of protection, Int. J. Mol. Sci., 20, 10.3390/ijms20081912 · DOI
  49. Takiishi, 2017, Intestinal barrier and gut microbiota: shaping our immune responses throughout life, Tissue Barriers, 5, 10.1080/21688370.2017.1373208 · DOI · Paper page
  50. Salvo Romero, 2015, The intestinal barrier function and its involvement in digestive disease, Rev. Esp. Enferm. Dig., 107, 686
  51. Wang, 2017, Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions, Am. J. Physiol. Cell Physiol., 312, C438, 10.1152/ajpcell.00235.2016 · DOI
  52. Wang, 2012, Curcumin ameliorates hydrogen peroxide-induced epithelial barrier disruption by upregulating heme oxygenase-1 expression in human intestinal epithelial cells, Dig. Dis. Sci., 57, 1792, 10.1007/s10620-012-2094-7 · DOI
  53. Ghosh, 2014, Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice--role of intestinal permeability and macrophage activation, PLoS One, 9, 10.1371/journal.pone.0108577 · DOI
  54. Li, 2014, Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy, World J. Gastroenterol., 20, 17699, 10.3748/wjg.v20.i47.17699 · DOI
  55. Yesudhas, 2014, Multiple roles of toll-like receptor 4 in colorectal cancer, Front. Immunol., 5, 334, 10.3389/fimmu.2014.00334 · DOI
  56. Zhu, 2014, Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury, J. Neuroinflammation, 11, 59, 10.1186/1742-2094-11-59 · DOI
  57. Fu, 2014, Curcumin attenuates inflammatory responses by suppressing TLR4-mediated NF-kappaB signaling pathway in lipopolysaccharide-induced mastitis in mice, Int. Immunopharmacol., 20, 54, 10.1016/j.intimp.2014.01.024 · DOI
  58. Jobin, 1999, Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity, J. Immunol., 163, 3474, 10.4049/jimmunol.163.6.3474 · DOI
  59. Moon, 2006, Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets, Biol. Pharm. Bull., 29, 1470, 10.1248/bpb.29.1470 · DOI
  60. Shi, 2016, Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer, Gut, 65, 1470, 10.1136/gutjnl-2014-308455 · DOI
  61. Schaefer, 2015, MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis, BMC Immunol., 16, 5, 10.1186/s12865-015-0069-0 · DOI
  62. Thorlacius-Ussing, 2017, Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with inflammatory bowel disease, Inflamm. Bowel Dis., 23, 739, 10.1097/MIB.0000000000001086 · DOI
  63. Mudduluru, 2011, Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer, Biosci. Rep., 31, 185, 10.1042/BSR20100065 · DOI · Paper page
  64. Cherukuri, 2014, Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice, Mol. Oncol., 8, 169, 10.1016/j.molonc.2013.10.009 · DOI
  65. Xiang, 2012, Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma, Mol. Med. Rep., 6, 973, 10.3892/mmr.2012.1046 · DOI
  66. Cox, 2004, Colorectal cancer study, polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer, Br. J. Cancer, 91, 339, 10.1038/sj.bjc.6601906 · DOI
  67. Goel, 2001, Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells, Cancer Lett., 172, 111, 10.1016/S0304-3835(01)00655-3 · DOI
  68. Plummer, 1999, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex, Oncogene, 18, 6013, 10.1038/sj.onc.1202980 · DOI
  69. Villegas, 2011, Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice, Mol. Nutr. Food Res., 55, 259, 10.1002/mnfr.201000225 · DOI
  70. Kubota, 2012, Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice, Nutr. Cancer, 64, 72, 10.1080/01635581.2012.630554 · DOI
  71. Zhong, 2018, The role of tumor-associated macrophages in colorectal carcinoma progression, Cell. Physiol. Biochem., 45, 356, 10.1159/000486816 · DOI
  72. Norton, 2015, Immune cell interplay in colorectal cancer prognosis, World J. Gastrointest. Oncol., 7, 221, 10.4251/wjgo.v7.i10.221 · DOI
  73. Gao, 2015, Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13, J. Mol. Cell. Cardiol., 85, 131, 10.1016/j.yjmcc.2015.04.025 · DOI
  74. Zhou, 2015, Curcumin modulates macrophage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways, Cell. Physiol. Biochem., 36, 631, 10.1159/000430126 · DOI
  75. Mohammadi, 2019, Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent, J. Nutr. Biochem., 66, 1, 10.1016/j.jnutbio.2018.12.005 · DOI
  76. Xu, 2017, Curcumin up regulates T helper 1 cells in patients with colon cancer, Am. J. Transl. Res., 9, 1866
  77. Rahimi, 2019, Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states, Autoimmun. Rev., 18, 738, 10.1016/j.autrev.2019.05.012 · DOI
  78. Shafabakhsh, 2019, Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy, Pharmacol. Res., 147, 10.1016/j.phrs.2019.104353 · DOI
  79. Burada, 2015, Autophagy in colorectal cancer: an important switch from physiology to pathology, World J. Gastrointest. Oncol., 7, 271, 10.4251/wjgo.v7.i11.271 · DOI
  80. Chen, 2019, Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy, Mol. Cancer, 18, 101, 10.1186/s12943-019-1030-2 · DOI
  81. Udristioiu, 2019, Autophagy dysfunctions associated with cancer cells and their therapeutic implications, Biomed. Pharmacother., 115, 10.1016/j.biopha.2019.108892 · DOI
  82. Condello, 2019, Targeting autophagy to overcome human diseases, Int. J. Mol. Sci., 20, 10.3390/ijms20030725 · DOI
  83. Liu, 2019, Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells, Arch. Gynecol. Obstet., 299, 1627, 10.1007/s00404-019-05058-3 · DOI
  84. Liu, 2018, Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway, Oncol. Rep., 39, 1523
  85. White, 2016, Autophagy and p53, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a026120 · DOI
  86. He, 2011, Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin, Cancer Invest., 29, 208, 10.3109/07357907.2010.550592 · DOI
  87. Sun, 2019, Alpha-hederin induces autophagic cell death in colorectal cancer cells through reactive oxygen species dependent AMPK/mTOR signaling pathway activation, Int. J. Oncol., 54, 1601
  88. Sun, 2017, AMP-activated protein kinase: a therapeutic target in intestinal diseases, Open Biol., 7, 10.1098/rsob.170104 · DOI
  89. Song, 2014, Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer, Cell Death Dis., 5, e1504, 10.1038/cddis.2014.463 · DOI
  90. Thent, 2017, Is metformin a therapeutic paradigm for colorectal cancer: insight into the molecular pathway?, Curr. Drug Targets, 18, 734, 10.2174/1389450118666161205125548 · DOI
  91. Liu, 2017, Curcumin activates AMPK pathway and regulates lipid metabolism in rats following prolonged clozapine exposure, Front. Neurosci., 11, 558, 10.3389/fnins.2017.00558 · DOI
  92. Zhu, 2018, Cancer stem cells and tumorigenesis, Biophys. Rep., 4, 178, 10.1007/s41048-018-0062-2 · DOI
  93. Munro, 2018, Cancer stem cells in colorectal cancer: a review, J. Clin. Pathol., 71, 110, 10.1136/jclinpath-2017-204739 · DOI
  94. Visvader, 2012, Cancer stem cells: current status and evolving complexities, Cell Stem Cell, 10, 717, 10.1016/j.stem.2012.05.007 · DOI
  95. Boman, 2004, Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population, Am. J. Pathol., 165, 1489, 10.1016/S0002-9440(10)63407-4 · DOI
  96. Nautiyal, 2011, Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells, J. Mol. Signal., 6, 7, 10.1186/1750-2187-6-7 · DOI
  97. Huang, 2016, Curcumin induces apoptosis of colorectal cancer stem cells by coupling with CD44 marker, J. Agric. Food Chem., 64, 2247, 10.1021/acs.jafc.5b05649 · DOI
  98. Buhrmann, 2014, Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT, PLoS One, 9, 10.1371/journal.pone.0107514 · DOI
  99. Ramasamy, 2015, Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy, Cancer Cell Int., 15, 96, 10.1186/s12935-015-0241-x · DOI
  100. Kagohara, 2018, Epigenetic regulation of gene expression in cancer: techniques, resources and analysis, Brief. Funct. Genomics, 17, 49, 10.1093/bfgp/elx018 · DOI
  101. Esteller, 2008, Epigenetics in cancer, N. Engl. J. Med., 358, 1148, 10.1056/NEJMra072067 · DOI
  102. Guo, 2015, Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1, Biochem. Pharmacol., 94, 69, 10.1016/j.bcp.2015.01.009 · DOI
  103. Jiang, 2015, Curcumin reactivates silenced tumor suppressor gene RARbeta by reducing DNA methylation, Phytother. Res., 29, 1237, 10.1002/ptr.5373 · DOI
  104. Chatterjee, 2019, Curcumin-mediated demethylation of the proximal promoter CpG island enhances the KLF4 recruitment that leads to increased expression of p21Cip1 in vitro, J. Cell. Biochem., 120, 809, 10.1002/jcb.27442 · DOI
  105. Guo, 2018, DNA methylome and transcriptome alterations and cancer prevention by curcumin in colitis-accelerated colon cancer in mice, Carcinogenesis, 39, 669, 10.1093/carcin/bgy043 · DOI
  106. Singh, 2017, Histone deacetylase inhibitors for the treatment of colorectal cancer: recent progress and future prospects, Curr. Cancer Drug Targets, 17, 456, 10.2174/1568009617666170109150134 · DOI
  107. Bora-Tatar, 2009, Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies, Bioorg. Med. Chem., 17, 5219, 10.1016/j.bmc.2009.05.042 · DOI
  108. Chen, 2013, Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases, Carcinogenesis, 34, 1442, 10.1093/carcin/bgt070 · DOI
  109. Chen, 2007, Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells, Basic Clin. Pharmacol. Toxicol., 101, 427, 10.1111/j.1742-7843.2007.00142.x · DOI
  110. Hu, 2009, Curcumin-induced histone acetylation in malignant hematologic cells, J. Huazhong Univ. Sci. Technol. Med. Sci., 29, 25, 10.1007/s11596-009-0105-5 · DOI
  111. Gandhy, 2012, Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs, BMC Cancer, 12, 564, 10.1186/1471-2407-12-564 · DOI
  112. Carroll, 2011, Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia, Cancer Prev. Res. (Phila), 4, 354, 10.1158/1940-6207.CAPR-10-0098 · DOI
  113. Cruz-Correa, 2018, Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis, Gastroenterology, 155, 668, 10.1053/j.gastro.2018.05.031 · DOI
  114. Cruz-Correa, 2006, Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis, Clin. Gastroenterol. Hepatol., 4, 1035, 10.1016/j.cgh.2006.03.020 · DOI
  115. Sharma, 2004, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance, Clin. Cancer Res., 10, 6847, 10.1158/1078-0432.CCR-04-0744 · DOI
  116. Sharma, 2001, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, Clin. Cancer Res., 7, 1894
  117. James, 2015, Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy, Cancer Lett., 364, 135, 10.1016/j.canlet.2015.05.005 · DOI
  118. Liao, 2018, Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma, Arch. Oral Biol., 92, 32, 10.1016/j.archoralbio.2018.04.015 · DOI
  119. Zou, 2018, Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer, J. Cell. Biochem., 119, 1420, 10.1002/jcb.26302 · DOI
  120. Liu, 2016, Oral bioavailability of curcumin: problems and advancements, J. Drug Target, 24, 694, 10.3109/1061186X.2016.1157883 · DOI
  121. Toden, 2017, The holy grail of curcumin and its efficacy in various diseases: is bioavailability truly a big concern?, J. Restor. Med., 6, 27, 10.14200/jrm.2017.6.0101 · DOI
  122. Jayaprakasha, 2016, Enhanced colon cancer chemoprevention of curcumin by nanoencapsulation with whey protein, Eur. J. Pharmacol., 789, 291, 10.1016/j.ejphar.2016.07.017 · DOI
  123. Chaurasia, 2016, Curcumin-polymeric nanoparticles against colon-26 tumor-bearing mice: cytotoxicity, pharmacokinetic and anticancer efficacy studies, Drug Dev. Ind. Pharm., 42, 694, 10.3109/03639045.2015.1064941 · DOI
  124. Yogosawa, 2012, Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells, J. Nat. Prod., 75, 2088, 10.1021/np300465f · DOI
  125. Cuomo, 2011, Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation, J. Nat. Prod., 74, 664, 10.1021/np1007262 · DOI
  126. Howells, 2011, Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo, Int. J. Cancer, 129, 476, 10.1002/ijc.25670 · DOI
  127. Ghoneim, 2009, Effects of curcumin on ethanol-induced hepatocyte necrosis and apoptosis: implication of lipid peroxidation and cytochrome c, Naunyn Schmiedebergs Arch. Pharmacol., 379, 47, 10.1007/s00210-008-0335-2 · DOI
  128. Jiao, 2009, Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator, Blood, 113, 462, 10.1182/blood-2008-05-155952 · DOI · Paper page
  129. Zhang, 2018, Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT8/5Fu human colorectal cancer cell line, Mol. Med. Rep., 18, 5409
  130. Zhu, 2018, Curcumin induces autophagy via inhibition of yes-associated protein (YAP) in human colon cancer cells, Med. Sci. Monit., 24, 7035, 10.12659/MSM.910650 · DOI
  131. Su, 2018, Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells, Int. J. Oncol., 53, 1343
  132. Lee, 2018, Curcumin suppresses oncogenicity of human colon cancer cells by covalently modifying the cysteine 67 residue of SIRT1, Cancer Lett., 431, 219, 10.1016/j.canlet.2018.05.036 · DOI
  133. Huang, 2017, Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway, Oncotarget, 8, 40264, 10.18632/oncotarget.16828 · DOI
  134. Tong, 2016, Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-kappaB, uPA activator and MMP9, Oncol. Lett., 12, 4139, 10.3892/ol.2016.5148 · DOI
  135. Adeyeni, 2016, BMI1 is downregulated by the natural compound curcumin, but not by bisdemethoxycurcumin and dimethoxycurcumin, Physiol. Rep., 4, 10.14814/phy2.12906 · DOI
  136. Ruiz de Porras, 2016, Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-kappaB signalling pathway, Sci. Rep., 6, 24675, 10.1038/srep24675 · DOI
  137. Zhang, 2016, Curcumin inhibits tumor epithelialmesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells, Oncol. Rep., 35, 2615, 10.3892/or.2016.4669 · DOI
  138. Guo, 2015, Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis, Phytother. Res., 29, 357, 10.1002/ptr.5257 · DOI
  139. Wang, 2015, Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro, Anticancer Drugs, 26, 15, 10.1097/CAD.0000000000000132 · DOI
  140. Jiang, 2014, PI3K/Akt pathway involving into apoptosis and invasion in human colon cancer cells LoVo, Mol. Biol. Rep., 41, 3359, 10.1007/s11033-014-3198-2 · DOI
  141. Chen, 2013, Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer, Evid. Complement. Alternat. Med., 2013
  142. Shehzad, 2013, Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53, Mol. Cells, 35, 526, 10.1007/s10059-013-0038-5 · DOI
  143. Blakemore, 2013, Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage, Carcinogenesis, 34, 351, 10.1093/carcin/bgs345 · DOI
  144. Lu, 2011, Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells, Mol. Cell. Biochem., 354, 247, 10.1007/s11010-011-0824-3 · DOI
  145. Watson, 2010, Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells, Cancer Lett., 297, 1, 10.1016/j.canlet.2010.04.018 · DOI
  146. Patel, 2008, Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R, Int. J. Cancer, 122, 267, 10.1002/ijc.23097 · DOI
  147. Sandur, 2009, Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity, Int. J. Radiat. Oncol. Biol. Phys., 75, 534, 10.1016/j.ijrobp.2009.06.034 · DOI
  148. Johnson, 2009, Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling, Anticancer Res., 29, 3185
  149. Kunnumakkara, 2009, Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model, Int. J. Cancer, 125, 2187, 10.1002/ijc.24593 · DOI
  150. Milacic, 2008, Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo, Cancer Res., 68, 7283, 10.1158/0008-5472.CAN-07-6246 · DOI
  151. Kunnumakkara, 2008, Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products, Clin. Cancer Res., 14, 2128, 10.1158/1078-0432.CCR-07-4722 · DOI
  152. Yin, 2019, Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway, Onco Targets Ther., 12, 3893, 10.2147/OTT.S199601 · DOI
  153. Irving, 2015, Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial, Trials, 16, 110, 10.1186/s13063-015-0641-1 · DOI
  154. Wu, 2017, Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside, Biochim. Biophys. Acta Rev. Cancer, 1868, 538, 10.1016/j.bbcan.2017.10.001 · DOI
  155. Siddiqui, 2009, Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice, Br. J. Nutr., 102, 967, 10.1017/S0007114509345250 · DOI
  156. Adachi, 2020, Theracurmin inhibits intestinal polyp development in Apc-mutant mice by inhibiting inflammation-related factors, Cancer Sci., 10.1111/cas.14329 · DOI
  157. Greil, 2018, A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc TM) in patients with locally advanced or metastatic cancer, Cancer Chemother. Pharmacol., 82, 695, 10.1007/s00280-018-3654-0 · DOI
  158. Li, 2007, Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer, Mol. Cancer Ther., 6, 1276, 10.1158/1535-7163.MCT-06-0556 · DOI
  159. Moradi-Marjaneh, 2018, Phytosomal curcumin elicits anti-tumor properties through suppression of angiogenesis, cell proliferation and induction of oxidative stress in colorectal cancer, Curr. Pharm. Des., 24, 4626, 10.2174/1381612825666190110145151 · DOI
  160. Lotfi-Attari, 2017, Co-delivery of curcumin and chrysin by polymeric nanoparticles inhibit synergistically growth and hTERT gene expression in human colorectal cancer cells, Nutr. Cancer, 69, 1290, 10.1080/01635581.2017.1367932 · DOI

Cited by

Sorted by citations

Metadata

Authors
Weng, W., & Goel, A.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2022-05
Volume
80
Pages
73-86
ISSN
1044-579X
DOI
10.1016/j.semcancer.2020.02.011
PMC
PMC7438305
Cited by
287
References
8
Language
en
Licence
Funders
  • National Cancer Institute, National Institutes of Health (R01 CA72851, CA181572, CA184792, CA202797, U01 CA187956)
  • Baylor Sammons Cancer Center and Foundation
  • Baylor Scott & White Research Institute
  • Beckman Research Institute of City of Hope
  • National Natural Science Foundation of China (81672826, 81874179)
  • Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ044)
  • Shanghai Pujiang Talent Plan (18PJD047)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review